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Summary Previously, we described FGF-1- or FGF-4-transfected MCF-7 breast carcinoma cells which are
tumorigenic and metastatic in untreated or tamoxifen-treated ovariectomised nude mice. In this study, we have
assessed the effects of AGM-1470, an antiangiogenic agent, and pentosan polysulphate (PPS), an agent that
abrogates the effects of FGFs, on tumour growth and metastasis produced by these FGF-transfected MCF-7
cells. Untreated or tamoxifen-treated ovariectomised mice were injected with FGF-transfected cells, treated
with AGM-1470 or PPS, and tumour growth and metastasis analysed. The sensitivity of FGF-transfected and
parental MCF-7 cells to AGM-1470 or PPS was also determined in vitro. Both AGM-1470 and PPS inhibited
tumour growth in otherwise untreated or tamoxifen-treated mice injected with either FGF- or FGF-4-
transfected MCF-7 cells. This effect was more reliably seen in tamoxifen-treated animals. AGM-1470 was about
105 times less potent in inhibiting the anchorage-dependent growth of parental MCF-7 or FGF-transfected
MCF-7 cells than in inhibiting the growth of human umbilical vein endothelial cells. PPS did not affect the in
vitro growth of the transfectants or parental cells. Thus, the growth-inhibitory effect on tumours was in excess
of the effect of either drug on the same cells in tissue culture, implying that stromal elements are important
determinants of the effects of these drugs. There was a positive correlation between tumour size and the extent
of proximal lymph node metastasis. However, neither drug had a significant effect on the extent of metastasis
to proximal or distal lymph nodes or lungs. AGM-1470 or PPS may be helpful in cases of breast carcinoma in
which angiogenesis is due to expression of FGFs by the tumour cells and may be more effective when
combined with tamoxifen.
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The acquisition of the ability to promote neovascularisation
has been described as a seminal event in tumorigenicity,
enabling uncontrolled growth, invasion and metastasis of a
previously indolent lesion (Folkman et al., 1989, Folkman
Shing, 1992; Weinstat-Saslow and Steeg, 1994). We have
previously transfected MCF-7 breast carcinoma cells with
expression vectors for one of two angiogenic growth factors,
FGF-4 (McLeskey et al., 1993) or FGF-I (Zhang et al.,
1995). These transfections have produced cell lines that are
tumorigenic and metastatic in ovariectomised and tamoxifen-
treated athymic nude mice. This behaviour is in direct
contrast to parental MCF-7 cells, which require oestrogen
supplementation for formation of small, poorly metastatic
tumours in ovariectomised nude mice (Soule and McGrath,
1980; Osborne et al., 1985). The change in in vivo phenotype
produced by these transfections may mimic the transition
that occurs in oestrogen receptor-positive human breast
carcinomas which are initially responsive to antioestrogen
therapy. After prolonged antioestrogen therapy, such
carcinomas may become refractory to the antioestrogen and
acquire a more invasive and metastatic phenotype, ultimately
leading to the death of the patient.
Although the acquisition of angiogenic ability may be
multifactorial in a given tumour and may involve different
mechanisms in different tumours, there is evidence that FGFs
or FGF receptors may be involved in some transitions of
tumours to an angiogenic phenotype. Expression of FGFs
has been associated with a switch to an angiogenic phenotype
in fibrosarcomas (Kandel et al., 1991), and is prominent in
melanomas (Halaban, 1993) and in brain tumours which are
very vascular (Brem et al., 1992). Several investigators have
shown specific FGF receptors to be newly expressed at a time
of phenotypic transition of tumours from indolent to
aggressive or metastatic (Yan et al., 1993; Yamaguchi et
al., 1994; Luqmani et al., 1995; Smith et al., 1994; Penault-
Llorca et al., 1995; Gomm et al., 1991). We have found FGF-
1 or FGF-2 mRNA to be expressed in many breast
carcinoma specimens (Ding et al., 1992) and FGF ligands
to be preferentially expressed by oestrogen receptor-negative
breast carcinoma cell lines (Flamm et al., 1989). Amplified
and/or overexpressed FGF receptors have been identified in
breast carcinoma specimens, implying that FGF signalling
contributes to the phenotype of these tumours (Adnane et al.,
1991; Jaakkola et al., 1993).
Since the transfection of FGFs into MCF-7 cells, an
oestrogen-dependent, poorly tumorigenic and relatively non-
metastatic breast carcinoma cell line, has produced cell lines
which cause aggressive, metastasising tumours in the absence
of oestrogenic growth stimulation, it seemed important to test
the hypothesis that this phenotypic change is the result of
increased angiogenesis. Therefore, we have treated ovariecto-
mised mice injected with either FGF-1- or FGF-4-transfected
MCF-7 cells with AGM-1470 (also known as TNP470), an
antiangiogenic drug (Ingber et al., 1990; Kusaka et al., 1991;
Yamamoto et al., 1994; O'Reilly et al., 1995), or pentosan
polysulphate (PPS), a drug which binds FGFs as well as
other heparin-binding growth factors (Belford et al., 1993)
and has been shown to bind to FGFR-1 (Pantoliano et al.,
1994), and which under some circumstances inhibits the
effects of FGFs (Wellstein et al., 1991; Zugmaier et al., 1992).
We now report that both agents were growth inhibitory to
tumours produced by FGF-transfected cells in both
ovariectomised and tamoxifen-treated mice. These effects
were in excess of the in vitro effects of these agents on the
transfected and parental cells. In spite of the negative effect
of each drug on tumour growth and contrary to published
reports of an inhibitory effect of AGM-1470 on metastasis in
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other systems (Yanase et al., 1993; Yamaoka et al., 1993;
Brem et al., 1993; Mori et al., 1995; Kato et al., 1994;
Kurebayashi et al., 1994), neither drug had a detectable
inhibitory effect on metastasis in this system.
Methods
Cell lines
MKL-4 cells are MCF-7 cells sequentially transfected with
expression vectors for FGF-4 and lacZ as described
(McLeskey et al., 1993; Kurebayashi et al., 1993). oa-21 and
a-10 cells are clonal G-418-resistant cell lines isolated from a
transfection of ML-20 cells [MCF-7 cells first transfected with
an expression vector for lacZ (Kurebayashi et al., 1993)] with
an expression vector encoding amino acids 21-145 of FGF-l
(Burgess et al., 1986; Burgess and Maciag, 1989), and further
characterised as producing high levels of the transfected
protein and forming tumours in nude mice (Zhang et al.,
1995). MCF-7 cells were approximately passage 60.
Drugs
Pentosan polysulphate (PPS) was obtained from beneChemie,
Munich, Germany. AGM-1740 (also known as TNP 470) was
kindly supplied by Katsuichi Sudo, Takeda Chemical
Industries, Osaka, Japan. Tamoxifen pellets (5 mg, 60 day
release) were obtained from Innovative Research, Toledo,
OH, USA.
Cell culture and injection of mice
Cells were maintained in improved minimal essential medium
(IMEM) supplemented with 5% fetal bovine serum (FBS) in
a 5% carbon dioxide, 37°C incubator. On the day of
injection, cells were scraped into their normal growth
medium and viable cells were counted using trypan blue
exclusion. Ten million viable cells were injected into the
upper right mammary fat pad of each mouse in an injection
volume of 0.15 ml. This number of injected cells was used to
produce 100% tumour take (McLeskey et al., 1993) and is
consistent with the numbers ofcells injected by others (Haran
et al., 1994). Two- to 4-week-old virgin athymic nude mice
were ovariectomised approximately 2 weeks before each
experiment. At the beginning of the experiment, the mice
were approximately four- to six-weeks-old and weighed
approximately 20 g. Mice were randomised into groups of
five and sustained-release tamoxifen pellets (Innovative
Research, Toledo, OH, USA) were implanted in the
interscapular area as described (McLeskey et al., 1993) for
half of the groups. Drug treatments were begun the following
day. PPS was injected intraperitoneally at a dose of
5 mg kg-' in 0.1 ml phosphate-buffered saline (PBS) 6 days
per week. AGM-1470 was injected subcutaneously at a dose
of 30 mg kg-' in 0.1 ml of 30% ethanol in PBS three times
per week. The control group received subcutaneous 0.1 ml
injections of 30% ethanol in PBS. All agents were
administered for the duration of the study. Tumours were
measured in three dimensions twice weekly with calipers.
Tumour volume was calculated as the product of the largest
dimension, the orthogonal measurement and tumour thick-
ness. For some experiments, dissected tumours were weighed
at the time of sacrifice.
In vitro growth curves
Ten thousand MCF-7 and FGF-transfected MCF-7 cells per
well were plated in IMEM with 5% FBS in 24-well plates
and allowed to attach overnight. Treatments as indicated in a
final volume of 1 ml were added on the following day (day
0). Untreated wells received the ethanol vehicle ofAGM-1470
(0.1%). Cells were harvested with 0.1 mM EDTA in PBS on
appropriate days and counted using a Coulter automated cell
counter. Human umbilical vein endothelial cells (HUVEC)
were plated in 24-well plates at 10 000 cells per well using
their normal growth medium (IMEM supplemented with
10% FBS, 10 ng ml-' FGF-1, and 10 jug ml-' heparin).
Drug treatments were added the day following plating. Cells
were harvested as above and counted using a haemocyt-
ometer.
Detection and rating of metastases
Metastases in proximal axillary and distal axillary and
inguinal lymph nodes and selected whole organs (brain,
kidneys, liver, spleen, lungs and heart) were harvested, fixed
in 2% formaldehyde, 0.2% glyceraldehyde for 2-3 h, and
subjected to staining using X-gal (5-bromo-4-chloro-d-
indoyl-fl-D-galactopyranoside) (1 mg ml-' X-gal in 5 mM
potassium ferrocyanide, 5 mM potassium ferricyanide,
2 mm magnesium chloride in PBS) overnight at 40C.
Organs were examined under a dissecting microscope and
rated for the presence of blue-staining metastases as
described (Kurebayashi et al., 1993). Metastases were rated
according to the following rating system: 0, no visible blue
spots; 1+, few diffuse blue spots (less than about 5) or one
microscopic focus of a few blue spots; 2+, diffuse blue spots
(about 5-15) or several foci of a few blue spots; 3+, many
diffuse blue spots (about 15-50) or a barely visible
macroscopic focus of blue; 4+, very many blue spots
(more than about 50) or a large macroscopic focus of blue
(Kurebayashi et al., 1993).
Statistical analysis of tumour growth
Only mice which survived until the end of the experiment
were included in the statistical analysis. (Three mice expired
of unknown causes, not related to tumour burden, during the
course of the four experiments.) Mean tumour volume for
each treatment group was obtained using the calculated
volumes of each tumour, with zeros being used as the volume
when no tumour arose in an animal.
Because the data included tumour volume measurements
at multiple time points for each animal, and variances
differed between treatment groups and over time, repeated
measures analysis of variance (RMANOVA) was used to
analyse the data (Heitjan et al., 1993). This analysis is
considerably more powerful than analyses which compare
tumour growth at a single time point. Lack of normality was
an inconsistent finding and logarithmic transformations did
not improve model fit, so the untransformed data were used
for all analyses described here.
The effects of PPS and AGM-1470 were evaluated, singly
and in combination, in both untreated and tamoxifen-treated
mice. A 2 x 3 factorial design was used, resulting in the
following eight treatment groups, in which each study drug
occurs in four of the treatment groups: (1) untreated; (2)
AGM-1470 alone; (3) PPS alone; (4) AGM-1470+PPS; (5)
tamoxifen alone; (6) tamoxifen +AGM-1470; (7) tamoxi-
fen+PPS; (8) tamoxifen +AGM-1470 +PPS.
The analyses were conducted in two ways. The first
analysis considered the eight groups above as distinct
treatment groups and compared mean tumour volume
between pairs of treatment groups at successive time points.
This analysis also allowed assessment of interactions between
drugs. Interaction is said to occur when the measured impact
of two treatments in combination is either significantly
greater or significantly less than the sum of the effects of
each treatment given separately. Interaction is a statistical
concept which can suggest, but does not prove, biological
synergy or antagonism.
However, these pairwise analyses do not use all
information on a particular treatment group. For example,
the effect of PPS can be evaluated by comparing group 3 vs
group 1, but that analysis ignores additional information on
the effect of PPS derived from comparing group 7 vs group 5.
Therefore, we undertook an additional analysis which derives
the effect of a drug by considering simultaneously allInhibition of in vivo growth by AGM-1470 and PPS
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treatment groups that include the drug vs all groups that do
not include it. This approach essentially provides an overall
test of the drug effect based on the maximum of information.
This analysis was used to augment the interpretation derived
from the first analysis.
Mammary fat pad injection of FGF-1-transfected cells is
sometimes associated with formation of a sac surrounding the
tumour which contains bloody fluid (Zhang et al., 1995), as
discussed in 'Results'. Tumour volume measurements are
then possibly confounded by the presence of the fluid-filled
sac. Because some of the tumour volume measurements for
tumours produced by FGF-1 transfectants included the
volume of the sac, we weighed the harvested tumours from
two of the experiments using these FGF- 1 transfectants.
These data were not normally distributed even upon
logarithmic transformation. Consequently, a one-way analy-
sis of variance (ANOVA) was used on the ranks of the mean
tumour weights for each treatment group. This non-
parametric test of significance at one time point does not
have the power of the RMANOVA conducted over multiple
time points on the tumour volume data described above and
thus may fail to detect a difference between treatment groups
when one in fact exists (type II error).
We used analysis of covariance to evaluate the drug effects
on the metastasis score for proximal, distant and lung
metastases, and a total metastasis score which summed all
three site-specific scores. This method allowed us to adjust for
the effects of tumour volume at the final time point. In
addition, we converted the score to a binary variable for
metastases present (yes vs no), or low vs high total metastasis
score (0,1 vs 2,3,4). Logistic regression was used to evaluate
this binary outcome, again adjusting for the effect of final
tumour volume. Because of the small number of animals per
treatment group, we included only the effects of single drugs
vs control in the models (e.g. main effect).
Results
Tumours produced by FGF-J- or FGF-4-transfected MCF-7
cells in nude mice are growth-inhibited by treatment with
pentosan polysulphate or AGM-1470
We treated ovariectomised mice injected with FGF-transfected
MCF-7 cells with pentosan polysulphate (PPS), an agent
which is capable of abrogating the effects of FGFs and other
heparin-binding growth factors in vitro and in vivo (Wellstein
et al., 1991; Zugmaier et al., 1992). This agent presumably acts
by binding to FGFs (Belford et al., 1993), preventing them
from reaching their receptors on tumour or stromal cells. PPS
also may bind to the heparin binding site of FGFR
(Pantoliano et al., 1994). By either mechanism, PPS would
be expected to abrogate both the autocrine and paracrine
effects of the transfected FGFs, reverting the cells back toward
their parental phenotype. Since FGFs are known angiogenic
factors, we also examined the contribution of the angiogenic
component to the tumorigenic phenotype of the transfectants
by treating ovariectomised mice injected with FGF-transfected
cells with AGM-1470. This agent has preferential toxicity for
endothelial cells (Kusaka et al., 1994; Antoine et al., 1994) and
is an inhibitor of angiogenesis in many assays (Ingber et al.,
1990; Kusaka et al., 1991; Yamamoto et al., 1994). Since we
have previously shown that tamoxifen treatment of mice
injected with FGF-4-transfected MCF-7 cells stimulates
tumour growth (McLeskey et al., 1993), we also tested the
effects of PPS or AGM-1470 on tumour growth of FGF
transfectants in tamoxifen-treated animals. Our rationale was
that abrogation of the effect (either angiogenesis alone with
AGM-1470 or all autocrine and paracrine effects with PPS)
responsible for the change in phenotype of the transfectants
would return them to their parental phenotype of being
growth inhibited by tamoxifen treatment. Thus, in these
experiments, tamoxifen treatment should be considered as a
condition affecting tumour growth rather than an anti-tumour
treatment.
The FGF-1-transfected MCF-7 cell lines we chose to use
in these experiments are transfected with an expression vector
encoding FGF-121-, ,, a biologically active form of FGF-1
that lacks the first 21 amino acids (Burgess et al., 1986;
Burgess and Maciag, 1989; Forough et al., 1993). Although
this species lacks a signal peptide sequence, FGF-I is present
in media conditioned by the transfectants. FGF-1-transfected
cells exhibit many of the same properties as the FGF-4
transfectants. They are tumorigenic in ovariectomised nude
mice without oestrogen supplementation and develop
micrometastases in the lymph nodes and lungs with high
frequency. One phenotype exhibited by FGF-l transfectants
that was not previously seen with FGF-4 transfectants is the
appearance of a sac filled with inflammatory exudate, which
does not contain tumour cells, surrounding the tumour in
some animals. This sac appears in 40-50% of tumours 1-2
weeks after tumour cell injection. As time progresses, the
tumour grows to completely fill the sac (Zhang et al., 1995).
To avoid possible error associated with tumour measure-
ments which included the volume of the sac in those instances
where it developed, we analysed results of experiments using
these cells in several ways below. The FGF-4-transfected cell
line used here, MKL-4, has been previously described
(McLeskey et al., 1993; Kurebayashi et al., 1993).
Tumour growth curves from four experiments, one with
FGF-4-transfected cells and three with FGF-1-transfected
cells, are depicted in Figure la-d. The information from
these curves is summarised in Table I, which includes relevant
pairwise comparisons of mean tumour volume between
treatment groups. For simplicity, this table only shows
comparisons measured at the final time point, but the
results for the entire curve are similar.
As can be seen from Figure Ia -d and Table I, PPS
reduced tumour volume in all experiments, but the effect was
larger and of greater statistical significance for tamoxifen-
treated than untreated animals. In other words, the decrease
in tumour volume for PPS+ tamoxifen vs tamoxifen alone
was greater than the decrease for PPS vs untreated control.
Table II indicates that the overall decrease in volume due to
PPS (i.e. over all time points and all treatment groups) was
significant for all but the second experiment involving the a-
21 clonal cell line of FGF-l transfectants (Figure lc), where a
marginally significant (P = 0.079) effect was noted. As noted
below, tumour volume measurements in this cell line are
confounded by the presence of a fluid-filled sac surrounding
the tumour. However, when post mortem tumour weights
from the oc-21 clonal line were compared in the experiment
depicted in Figure lc, PPS treatment also did not produce an
overall statistically significant effect (see below).
AGM-1470 also reduced tumour volume in all experi-
ments. However, as shown in Figure la-d and Table I, the
effect was larger in tamoxifen-treated animals. Table I shows
that, for each transfected cell line, the reduction in tumour
volume with AGM-1470 was smaller than that achieved with
PPS. Table II shows that the overall effect of AGM-1470 was
significant only for the a-21 FGF-1-transfected clonal cell line
in the first experiment using this line (Figure lb), while a
marginally significant effect (P=0.064) was observed for the
FGF-4 transfectants.
Although both PPS and AGM-1470 exhibited larger
effects in the presence of tamoxifen, the statistical tests for
interactions between each drug and tamoxifen were not
significant. This may reflect the large variability in individual
tumour volumes, as indicated by some of the large standard
errors in Table I and the small number of animals in each
treatment group.
Since PPS presumably reduces FGF-mediated effects in a
dose-dependent manner, we could therefore hypothesise that,
at some dose, PPS would abrogate the effects of FGFs
completely, retuming the transfectants to their parental
phenotype of being growth inhibited by tamoxifen. At the
dose used in these experiments, animals treated with PPS and
tamoxifen and injected with FGF-4-transfected cells had a
larger mean tumour volume than animals treated with PPSInhibition of in vivo growth by AGM-1470 and PPS
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Figure 1 Effects of AGM-1470 and PPS on growth of tumours produced by FGF-transfected MCF-7 cells. Ovariectomised nude
mice were injected as described with 10 million cells of the indicated cell line. Randomised groups of five mice each were treated
with indicated drugs as described. 0, vehicle (30% ETOH in PBS), *, tamoxifen, EC, PPS, *, PPS+tamoxifen, V, AGM-1470,
V, AGM-1470+tamoxifen. Error bars represent one standard error of the mean. (a) Growth of tumours produced by FGF-4
transfected MCF-7 cells (MKL-4 cells (Kurebayashi et al., 1993)). (b-d) Three experiments depicting the growth of tumour lesions
(sacs filled with bloody fluid containing the solid tumour or solid tumours without a sac) produced by two different clonal cell lines
of FGF-I transfected MCF-7 cells. (b) Clonal cell line a-21. (c) A second experiment with clonal cell line a-21. Inset depicts post-
mortem tumour weights of the dissected tumours after sacrifice. These measurements show that the sudden increase in volume of the
lesions in PPS-treated animals at day 50 represented growth of the sac filled with bloody fluid, not the tumours themselves. Symbols
represent individual tumour volumes. Bars represent mean volumes with error bars representing one s.e.m. None, no treatment; T,
tamoxifen; A, AGM-1470; P, PPS. Means and standard deviations of tumour weights are as follows: None, 294+ 154; tamoxifen,
402+252; AGM-1470, 58+47; AGM-1470+tamoxifen, 328+216; PPS, 14+14; PPS+tamoxifen, 16+6.9. (d) Clonal cell line a-10.
Inset depicts post-mortem tumour weights as in c. Means and standard deviations of tumour weights are as follows: None
270+242; tamoxifen, 646+244; AGM-1470, 26+24; AGM-1470+tamoxifen, 352+237; PPS, 11+5.5; PPS+tamoxifen, 83+82.
alone (Figure la). However, the stimulatory effect of
tamoxifen was not as large as that observed in otherwise
untreated animals. In contrast, animals injected with the
FGF-1-transfected cells had very small or no tumours in the
PPS-treated group, and the addition of tamoxifen did not
increase tumour growth or incidence (Figure lb-d). There-
fore, for the FGF-l transfectants, the stimulatory effect of
tamoxifen was not evident in PPS-treated animals. In fact, in
one experiment involving FGF-1 transfectants, PPS was
significantly antagonistic to the stimulatory effect of
tamoxifen (P=0.006) (Figure lb).
Giving a combination of AGM and PPS did not increase
the growth inhibitory effect of PPS alone in either otherwise
untreated or tamoxifen-treated animals in any cell lines tested
(data not shown). For some transfectants, the effect of the
combination was in between that of PPS and that of AGM-
1470. Since tumour growth was already inhibited by the
single treatments, the effect of the combination treatment was
necessarily small and thus we are unable to draw any reliable
conclusions concerning combinations of AGM-1470 and PPS.
Since PPS inhibited tumour growth to a greater degree
than AGM-1470 and since AGM-1470 is thought to be an
angiogenesis inhibitor, these data suggest that the increase in
tumorigenicity observed in FGF-transfected MCF-7 cells
when compared with parental MCF-7 cells is not solely due
to FGF-mediated angiogenesis. However, it is also possible
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Table I Effect of PPS and AGM-1470 on mean tumour volume in untreated or tamoxifen-treated mice
FGF-transfected cells injected
Treatment groups FGF-4 FGF-I FGF-J FGF-J
compared (Figure la) (Figure lb) (Figure Ic) (Figure Id)
Untreated 370+ 113.7* 494+ 274.4 1533 +805.0 1137+ 1006.5
PPS 117+ 14.9 24+ 14.6 642±623.6 248+ 152.6
P-value 0.101 0.034 0.315 0.390
Untreated 370+ 113.7 494±274.4 1533+805.0 1137± 1006.5
AGM-1470 137+35.1 332±71.6 342± 163.1 819±727.8
P-value 0.146 0.451 0.182 0.757
Tamoxifen alone 829+ 175.1 914+325.7 1365+821.6 4068+926.9
Tamoxifen + PPS 303+ 91.6 0+ 0.0 83± 75.5 482+432.3
P-value 0.002 0.001 0.151 0.002
Tamoxifen alone 829 ± 175.1 914+ 325.7 1365 + 821.6 4068 ±926.9
Tamoxifen +AGM-1470 421 ± 128.8 157 ± 75.0 792+ 597.8 2001 i 1119.9
P-value 0.014 0.003 0.515 0.052
This is an example of the comparison between pairs of treatment groups showing the effect of PPS and AGM-1470 on mean tumour volume
produced by injection of FGF transfected MCF-7 cells in otherwise untreated or tamoxifen-treated mice, using the final time point of each
experiment. *Mean tumour volumes in mm3 + s.e.m. Comparisons of other time points yielded similar P-values.
Table II Comparsion of effects over all treatments and time points
FGF-transfected cells injected
FGF-4 FGF-I FGF-1 FGF-I
Treatment (Figure la) (Figure lb) (Figure Ic) (Figure Id)
PPS 0.014 0.0007 0.079 0.0003
AGM 0.064 0.041 0.505 0.174
Statistical siginificance (P-values) is given for overall effects ofindividual treatments on mean tumour volume in tumours produced by FGF-1 or
FGF-4 transfected MCF-7 cells
that, at the dose used, AGM-1470 did not inhibit
angiogenesis as completely as PPS. Only two of seven
tumour-bearing mice treated with PPS alone from three
experiments with FGF-1 transfectants had a bloody fluid-
filled sac surrounding the tumour. Although we do not know
the origin of this sac and have no conclusive indication that it
represents ongoing angiogenesis other than the presence of
blood within it, its less frequent presence in PPS-treated
animals could be interpreted as evidence that FGF-1-
mediated effects on stromal tissue were more completely
inhibited in these animals by PPS treatment than with AGM-
1470 or other treatments. The sac in one of the PPS-treated
animals arose quite late in the experiment and the sudden rise
in volume of the tumour lesion owing to the sac formation in
this one animal is responsible for the sudden increase in mean
lesion volume of the PPS treatment group depicted in Figure
Ic. When the animals were sacrificed, the tumour inside this
sac was found to be quite small (Figure lc, inset).
The presence of this sac in some animals but not others
confounds the measurement of tumour volume, since it is
possible that the volume of the sac surrounding the tumour is
larger than the tumour inside, as exemplified above. For that
reason, at the time of tumour harvest in two experiments, we
weighed tumours produced by FGF-1-transfected cells. These
data are graphically depicted in the insets for Figure lc and
d. Since these data were not normally distributed even upon
logarithmic transformation, a one-way ANOVA on the ranks
of the mean tumour weights for each treatment group was
used to test for significant differences between treatment
groups. As mentioned, the use of this test at one time point
has less power than the RMANOVA which is able to
incorporate tumour data measured at multiple time points
(Heitjan et al., 1993). In the one-way ANOVA analysis of
effects of drug treatment on tumour weight, there were no
significant differences between treatment groups in the
experiment using the FGF-1 transfectants, clonal line a-21,
depicted in Figure lc (P =0.277). For the experiment depicted
in Figure Id using the a-10 clonal line, there were significant
differences in tumour weight between treatment groups
(P=0.032). Pairwise comparisons of treatment groups in
this experiment showed that the addition of PPS to tamoxifen
treatment produced a significantly lower mean tumour weight
when compared with tamoxifen alone (P=0.008). Thus,
although the statistical analysis of tumour weight measure-
ments at a single time point was not as powerful as the
RMANOVA, it did confirm the significant overall effect of
tamoxifen detected by the RMANOVA, as well as the
significance of the pairwise comparison of tamoxifen alone vs
tamoxifen plus PPS, in the experiment depicted in Figure ld.
Analysis of tumour weight measurements failed to detect an
overall effect of PPS which was detected by the RMANOVA.
However, there are substantial decreases in mean tumour
weight in both AGM-1470 and PPS treatment groups
(Figures lc and Id, insets). Interpretation of the effects of
these treatments was complicated by the wide variability in
tumour weights and the small sample size. In contrast to the
RMANOVA which measures tumour volume over the entire
growth curve, the one-way ANOVA at a single time point
lacks power. These problems were obviated to some degree in
the previous RMANOVA analysis which gained power by
using tumour data over the entire growth curve.
AGM-1470 and PPS have little effect on FGF transfectants or
parental MCF-7 cells in tissue culture
Growth requirements may differ substantially between in vitro
and in vivo environments, since many tumour cells are
immortal in tissue culture but are not tumorigenic in animals.
However, we felt that it was important to test the effects of
AGM-1470 and PPS on the FGF transfectants in tissue
culture in order to establish the presence of any directly toxic
effects of either drug on the transfected cells.
In anchorage-dependent growth assays, AGM-1470 has
been shown to have a cytostatic effect on endothelial cells
with an EC50 of about 10 pg ml-1 (Kusaka et al., 1994). The
batch of AGM-1470 used in these in vivo experiments was
tested on human umbilical vein endothelial cells (HUVEC)
and found to inhibit their growth with approximately the
same potency as has been published (Kusaka et al., 1994)
(data not shown). In anchorage-dependent growth assays
using FGF-transfected or parental MCF-7 cells, AGM-1470
inhibited growth with an EC50 of approximately 10-Inhibition of in vivo growth by AGM-1470 and PPS
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Figure 2 AGM-1470 and PPS have low potency for growth inhibition of parental or FGF transfected MCF-7 cells in vitro. Ten
thousand cells per well were plated in IMEM plus 5% FBS in 24-well plates and allowed to attach overnight. Medium was changed
to IMEM plus 5% FBS with indicated treatments on day 0. 0, 0.1% ethanol; O, 0.3,igml-
1 AGM-1470; V, 1 Mgml -l AGM-
1470; A, 3jigml- 1 AGM-1470; O, 10gml-V' AGM-1470; 0, 30jigml-1 AGM-1470. (a) FGF-l transfected cell line, o-10. (b)
FGF-I transfected cell line, a-21. (c) FGF-4 transfected cell line, MKL-4. (d) Parental MCF-7 cells.
30 jug ml-' (Figure 2a-d). PPS from the same batch as was
used in in vivo experiments at maximal concentrations of
100 ,ug ml-' had no effect on FGF-transfected parental
MCF-7 or HUVEC growth (data not shown). Thus, the
inhibitory effect of AGM-1470 or PPS on tumorigenicity in
vivo is probably not simply due to a non-specific toxic effect
on the growth of tumour cells and more likely involves one
or more tumour or stromal cell parameter(s) important for in
vivo growth.
AGM-1470 or PPS treatment does not affect metastasis of
FGF-transfected MCF-7 cells
As described (McLeskey et al., 1993; Kurebayashi et al.,
1993; Zhang et al., 1995), FGF-transfected MCF-7 cells are
reliably metastatic, primarily to proximal and distal lymph
nodes and lungs. In one investigation, the incidence of
metastases in FGF-4-transfected cells was correlated with size
of the tumour, with tumours greater than 100 mm3 having
100% incidence of metastasis to the proximal lymph node.
These metastases are detected by X-gal staining for fi-
galactosidase activity of the lacZ transfected cells. Thus,
microscopic metastases can be detected as well as macro-
scopic (Kurebayashi et al., 1993). Since angiogenesis has been
thought to be an important determinant of metastasis
(Weinstat-Saslow and Steeg 1994), it is possible that the
increased incidence of metastasis observed with FGF-
transfected MCF-7 cells is due to the increased angiogenesis
in the primary tumour or metastatic focus produced by the
transfected FGF. To test the hypothesis that decreasing the
angiogenic or other effects or the transfected FGF would
decrease the incidence of metastasis, we examined proximal
axillary and distal axillary and inguinal lymph nodes, and
selected organs (lungs, liver, brain, kidneys, spleen and heart)
using X-gal detection to disclose the presence of blue-staining
cancer cells expressing fl-galactosidase. Because the incidence
of metastasis in FGF-transfected cells had previously been
correlated with tumour size (Kurebayashi et al., 1993), we
wanted to know if tumours large enough that they would be
expected to metastasise failed to do so, or if tumours so small
that they would not be expected to metastasise, produced
metastasis. To visualise the results of this analysis, we used a
rating scale from 0-4 for the extent of metastasis in a given
organ (Kurebayashi et al., 1993) and plotted tumour volume
at the end of the experiment with relation to the extent of
metastasis (Figure 3a-f). Data from the experiments depicted
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Figure 3 PPS and AGM-1470 do not prevent metastasis of FGF-transfected MCF-7 cells. Lymph nodes and lungs from animals
injected with FGF-transfected MCF-7 cells were treated with X-gal to reveal blue-staining tumour cells. The extent of metastasis in
each organ was rated on a scale of 0 (absent) to 4 (extensive) as described by Kurebayashi et al. (1993). 0, vehicle (30% ETOH in
PBS); 0, tamoxifen; OI, PPS; *, PPS+tamoxifen; V, AGM-1470; 7, AGM-1470+tamoxifen. (a-c) MKL-4 cells (FGF-4
transfectants). (d-f) a-21 cells (FGF-I transfectants). (a and d) Proximal lymph nodes; (b,e) distal lymph nodes; (c,f) lungs.
in Figure la and Figure lb from proximal and distal lymph
node metastases and pulmonary micrometastases are pre-
sented, since these were sites most reliably involved. Because
of lower than expected rate of metastases in control groups in
the experiments depicted in Figure lc and d, data from these
experiments was not analysed. In addition, metastatic sites
other than lymph nodes and lungs were infrequently
involved, making statistical analysis of the incidence of
metastases at these sites impossible. The analyses were
conducted separately for each cell line. Linear regression
was used to show the correlation between tumour volume
and proximal lymph node metastases. For both cell lines
examined, the regression slope was significant (MKL-4 cells
in Figure 3a, P=0.012; a-21 cells in Figure 3d, P=0.029),
meaning that extent of metastasis was positively correlated
with tumour size in this study as it had been previously
(Kurebayashi et al., 1993). However, the correlations were
relatively low (r2 =0.17 and 0.22 for Figures 3a and d,
respectively). This indicates that tumour size accounts for
only a small proportion of the variability in extent of
metastasis (17% and 22%, respectively). Furthermore, the
extent of metastasis did not differ significantly among drug
treatment groups in either analysis of variance or logistic
regression models (data not shown).
Extent of metastasis was likely to be underestimated,
since the X-gal stain only penetrates the organ a few
millimetres and internal metastases remain undetected.
Another source of false-negative error for the FGF-4
transfectants (Figure la) is that only about 30% of these
cells were blue staining in vitro before injection (McLeskey
et al., 1996). False-positive error in metastasis detection is
not as likely, as reaction conditions minimise the ability of
endogenous #-gal activity to produce blue colour, and visual
inspection of the metastases under magnification leads to
rejection of non-specific blue staining. Thus, we feel that the
presence of metastases in AGM-1470- or PPS-treated
animals is an indication that these drug treatments as
administered in this study did not have a significant
inhibitory effect on metastasis.
Discussion
We have demonstrated a growth-inhibitory effect of AGM-
1470 and PPS on tumours produced by FGF-transfected
MCF-7 cells in ovariectomised and tamoxifen-treated nude
mice. These effects were present in four separate experiments
using three different FGF-transfected cell lines. Although the
statistical significance of the drug effects was not uniform
over all four experiments, it seems clear that PPS is growth
inhibitory for these tumours in most circumstances and
AGM-1470 is growth inhibitory for these tumours at least
under conditions of tamoxifen treatment (Tables I and 11).
Neither agent was able to abrogate tumour growth
completely in any experiment with the exception of the
combination of PPS and tamoxifen in one experiment
involving an FGF-1-transfected cell line (Figure lb). Since
we only used one dose of each agent, it might be argued that
the dose used was insufficient to abrogate completely the
effects of the transfected FGF. However, the doses used were
maximally tolerated doses for both drugs in our experience.
PPS is believed to act by binding to FGFs (Zugmaier et
al., 1992) or by occupying the heparin binding site on FGFRs
(Pantoliano et al., 1994). However, it also binds many other
heparin-binding growth factors (Zugmaier et al., 1992).
Moreover, PPS had no effect on in vitro growth of the
transfectants or the parental cells. Thus, the effects of PPS in
our experiments may be due to effects of PPS on heparin-
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binding growth factors other than FGF-1 or FGF-4 which
may be produced by the transfected or parental cells and
which may have paracrine effects on stromal cells. However,
since the transfected FGF is the factor responsible for the
increased tumorigenicity of these cells (McLeskey et al., 1993;
Zhang et al., 1995), we must conclude that the activity ofPPS
on the transfected FGF is at least one of the factors
responsible for the reduced tumour growth in PPS-treated
animals. When used in tamoxifen-treated animals, the
inhibitory effect of PPS on tumour growth was more often
significant over the four experiments (Table I). These data are
evidence for the activity of the transfected FGF in promoting
the tamoxifen stimulation of tumour growth in these
transfectants, but also suggest that tamoxifen may be
influencing some other factor which is stimulatory for
tumour growth in this model and which is also affected by
PPS.
We felt that the FGF-1-transfected MCF-7 cells, in
particular, might be an ideal cell line in which to test the
effects of an antiangiogenic drug such as AGM-1470. These
cells often form a sac filled with bloody fluid around the
tumour which sometimes is much larger than the tumour itself
(Zhang et al., 1995). We do not know the origin of this sac. It
is possible that it results from increased permeability of blood
vessels in the vicinity ofthe tumour or that it is the product of
excessive angiogenesis. If the latter is the case, giving an
antiangiogenic drug might inhibit its formation. Neither
AGM-1470 nor PPS completely prevented the formation of
the sac, although its appearance was limited to only one
animal and much delayed in PPS-treated animals (Figure ic).
Studies are underway to characterise the sac more fully and to
examine vascular patterns and architecture in these tumours.
We have shown the FGF-transfected and parental MCF-7
cells to be much less sensitive to the in vitro growth-inhibitory
effects ofAGM-1470 cells than endothelial cells (Figure 2). In
addition, the potency of our batch of AGM-1470 in
inhibiting in vitro endothelial cell growth agrees with
published reports (Kusaka et al., 1994) (data not shown).
When pharmacological doses of AGM-1470 are administered
to rats, plasma concentrations are below 1 jug ml-, except
for very short periods after subcutaneous or bolus
intravenous injection (K Sudo, personal communication).
As this is below the concentration required for growth
inhibition of the tumour cells in vitro, it is tempting to ascribe
the in vivo growth inhibition by AGM-1470 of tumours
produced by FGF-transfected cells to its preferential toxicity
for endothelial cells and resultant inhibition of angiogenesis.
This drug has been shown to affect cell cycle events in
cultured endothelial cells at concentrations below toxic
concentrations for tumour cells (Abe et al., 1994; Antoine
et al., 1994). However, the drug apparently is taken up into
many types of cells and has many metabolites (Placidi et al.,
1995), and neither the active species nor the site of action for
AGM-1470 in vivo has been determined, making it difficult to
know the concentration of the drug at its site of action.
Therefore, although specific inhibition of angiogenesis may
indeed be the mechanism whereby AGM-1470 inhibits
tumour growth, its general toxicity for tumour or other
cells cannot be excluded as a mediator of the inhibition of
tumour growth observed in this study.
AGM-1470 significantly inhibited tumour growth more
frequently in tamoxifen-treated animals than in otherwise
untreated ones (Table I). If AGM-1470 is indeed an
antiangiogenic drug, then the question is raised as to
whether the effects of tamoxifen in stimulating tumour
growth are due to a stimulation of angiogenesis which is
additive to that of the transfected FGF. This would be a
previously undescribed effect of tamoxifen. In fact, there are
some reports of antiangiogenic effects of tamoxifen using
cultured HUVEC cells (Gagliardi et al., 1995), CAM assays
(Gagliardi and Collins, 1993), and MRI imaging of tumours
(Haran et al., 1994). Therefore, if a proangiogenic effect of
tamoxifen exists in vivo in our model, a direct effect of
tamoxifen upon endothelial cells is unlikely. It is possible that
tamoxifen has an indirect effect on angiogenesis such as
increasing FGF production by the tumour cells or increasing
either the production or the effectiveness of another
angiogenic growth factor which can act in synergy with the
FGF. We do not find oestrogen or tamoxifen affects
expression of the transfected FGF-4 in MKL-4 cells (Miller
et al., 1994). Tamoxifen has been shown to increase
expression of TFG-,B by breast cancer cells in vitro (Knabbe
et al., 1987, 1991) or in vivo (Butta et al., 1992). TGF-# has
been shown to have a synergistic effect with FGF-2 in an in
vitro assay of angiogenesis (Gajdusek et al., 1993). Although
TGF-,B has been shown to inhibit the growth of both breast
carcinoma and endothelial cells in vitro (Knabbe et al., 1987;
Barnard et al., 1990; Raychaudhury and D'Amore, 1993), it
is not inhibitory to some strains of MCF-7 cells (Arteaga et
al., 1988) which may lack the type II TGF-,B receptor (Sun et
al., 1994; Roberts et al., 1995). Its effects in vivo are unclear
(Welch et al., 1990; Walker and Dearing 1992; Arteaga et al.,
1993; Dalal et al., 1993). Thus, tamoxifen-induced TGF-,B
expression in the tumour could be synergistic with the
transfected FGF in stimulating angiogenesis in vivo. If so, we
might expect that abrogating angiogenesis with AGM-1470
or abrogating the effect of heparin-binding growth factors
(both the FGF and the TFG-/3) with PPS would inhibit
growth of tumours produced by FGF transfectants in
tamoxifen-treated animals more significantly than in other-
wise untreated animals. Experiments are planned to
investigate this possibility.
The failure of both drugs to prevent metastasis in spite of
their inhibitory effects on tumour growth is surprising in light
of the previous correlation of the number of metastatic foci
of FGF-4 transfectants with tumour size (Kurebayashi et al.,
1993) and in light of previous reports that AGM-1470
decreased metastasis (Yanase et al., 1993; Yamaoka et al.,
1993; Brem et al., 1993; Kato et al., 1994; Mori et al., 1995).
We do not believe the metastases in our system are produced
by seeding of distant organs at the time of tumour cell
injection. The evidence to support this belief is the previously
mentioned correlation of extent of metastasis with tumour
size after injection of equal numbers of cells (Kurebayashi et
al., 1993) and the fact that in the past we have been unable to
detect blue-staining cells in the animals' distant organs
between 2 and 10 days after tumour cell injection (data not
shown). Moreover, we find that following tail vein injection
of these lacZ tagged cells, we are able to detect many blue
staining cells in multiple organs of the mice following
immediate sacrifice and X-gal staining. Within 48 to 96 h,
however, the blue staining cells are completely absent and no
tumours result in lungs or other sites (data not shown).
Moreover, our failure to find an effect of drug on metastases
must be interpreted with caution due to the small sample size.
With only five animals per drug group and the need to
incorporate three dummy variables into the models to
parameterise the drug effects, the power to detect differences
between groups was low. The discrepancy between our
findings and those of others may also be due to experimental
design, since metastasis may also be studied by injecting
tumour cells into the venous circulation (Yamaoka et al.,
1993; Mori et al., 1995; Kato et al., 1994) or by excising
primary tumours from untreated animals and then beginning
treatment during the period of presumed metastatic growth
(Yamaoka et al., 1993). In addition, other investigators have
not taken the size of the primary tumour into consideration
when evaluating the incidence of metastasis (Yanase et al.,
1993; Yamaoka et al., 1993; Brem et al., 1993; Kurebayashi
et al., 1994). Because we have previously shown the
correlation of tumour size with the number of metastatic
foci (Kurebayashi et al., 1993) or extent of metastasis in this
study, it would seem likely that decreasing tumour size by
any means should decrease the likelihood of metastasis.
However, determinants of metastasis and tumour growth are
probably different. Therefore, a different dose-response
relationship for these drugs might apply to determinants of
metastasis than applies to determinants of tumour growth inhbition of in vyvo growth by AGM-1470 and PPS
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our system. This situation could pertain if the drugs were to
act on each determinant throuah different mechanisms. Since
we have only limited information on the mechanism of action
of PPS or AGM-1470. it is difficult to comment on this
possibilitv.
In conclusion. we have shown a arowth-inhibitor- effect of
PPS and AGM-1470 on tumours produced by FGF-
transfected MCF-7 cells. These inhibitory effects confirm
the importance of the transfected FGF for the tumongienic
phenotype of the transfectants and also suggest that increased
angiogenesis is an important factor in this phenotype. Since
FGF-1 has been shown to be expressed in human breast
carcinomas (Ding et al.. 1992: Smith et al.. 1994: Penault-
Llorca et al.. 1995). it is possible that such therapeutic
modalities might become important in the treatment of cases
of human cancer where FGF or other heparin-binding
angiogenic growth factor production is a determinant of
tumour growth. Because the effect of the drups was more
pronounced in tamoxifen-treated animals. the use of these
agents in combination with tamoxifen or in women whose
cancer has become refractorv to tamoxifen mig.ht offer
additional benefit.
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